Zai Lab Ltd is a biopharmaceutical company. It focused on medicines for cancer, autoimmune and infectious diseases primarily in China. The company's product pipeline consists of ZL-2306, ZL-2401, ZL-2301, ZL-3101, ZL-2302 and ZL-1101 which are in clinical stage. Zai Lab Ltd is based in Pudong, China.
| Revenue (Most Recent Fiscal Year) | $398.99M |
| Net Income (Most Recent Fiscal Year) | $-257.10M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 8.26 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 4.26 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -60.26% |
| Net Margin (Trailing 12 Months) | -60.26% |
| Return on Equity (Trailing 12 Months) | -33.35% |
| Return on Assets (Trailing 12 Months) | -23.28% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.26 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.09 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 3.51 |
| Book Value per Share (Most Recent Fiscal Quarter) | $7.35 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.45 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.60 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.49 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 110.33M |
| Free Float | 104.86M |
| Market Capitalization | $3.45B |
| Average Volume (Last 20 Days) | 0.92M |
| Beta (Past 60 Months) | 1.04 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.96% |
| Percentage Held By Institutions (Latest 13F Reports) | 41.65% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |